Fidelity Investments’s Lexaria Bioscience LEXX Stock Holding History

Fidelity Investments’s Portfolio LEXX Stock Details LEXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$119	Buy	+14	New	+$152	﹤0.01%	5393

Other funds holding LEXX

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments's LEXX Position: Q2 2026 in Review

Fidelity Investments opened a new position in Lexaria Bioscience (LEXX) in Q2 2026: 14 shares worth $119. The stake represents ﹤0.01% of the portfolio and ranks #5393 among its holdings.

29 funds tracked by Wall St. Rank hold LEXX as of Q2 2026.

Fidelity Investments held 14 shares of Lexaria Bioscience worth $119 as of Q2 2026.
Lexaria Bioscience was a new Fidelity Investments position in Q2 2026.
Lexaria Bioscience made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #5393 holding.
29 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.